

If a conflict arises between a Clinical Payment and Coding Policy (“CPCP”) and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. “Plan documents” include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. BCBSIL may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSIL has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act (“HIPAA”) approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing (“UB”) Editor, American Medical Association (“AMA”), Current Procedural Terminology (“CPT®”), CPT® Assistant, Healthcare Common Procedure Coding System (“HCPCS”), ICD-10 CM and PCS, National Drug Codes (“NDC”), Diagnosis Related Group (“DRG”) guidelines, Centers for Medicare and Medicaid Services (“CMS”) National Correct Coding Initiative (“NCCI”) Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

## **Prenatal Screening**

**Policy Number: CPCPLAB014**

**Version 1.0**

**Enterprise Medical Policy Committee Approval Date: January 25, 2022**

**Plan Effective Date: May 1, 2022**

## **Description**

BCBSIL has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

## **Reimbursement Information:**

1. The following routine prenatal screening **may be reimbursable** for all pregnant women:
  - a. Screening for HIV infection
  - b. Screening for Chlamydia trachomatis infection
  - c. Screening for Neisseria gonorrhoea infection
  - d. Screening for hepatitis B
  - e. Screening for syphilis
  - f. Screening for hepatitis C

- g. Screening for bacteriuria
  - h. Screening for fetal aneuploidy in accordance with CPCPLAB022 Prenatal Screening for Fetal Aneuploidy
  - i. Screening for type 2 diabetes at the first prenatal visit
  - j. Screening for gestational diabetes during gestational weeks 24 – 28 and at the first prenatal visit if risk factors are present
  - k. Determination of blood type, Rh(D) status, and antibody status during the first prenatal visit, and repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24 to 28 weeks' gestation, unless the biological father is known to be Rh (D)-negative
  - l. Screening for anemia meets coverage criteria with a CBC or hemoglobin and hematocrit with mean corpuscular volume
  - m. Screening for Group B strep once, recommended during gestational weeks 36 to 37 by American College of Obstetricians and Gynecologists (ACOG)
  - n. Urinalysis and urine culture
  - o. Rubella antibody testing
  - p. Testing for varicella immunity
  - q. Screening for tuberculosis in pregnant women deemed to be at high risk for TB (i.e., women with close contact with individuals with active pulmonary / respiratory tuberculosis or highly contagious active tuberculosis and women who are immunocompromised)
2. Third trimester re-screening of Chlamydia trachomatis, Neisseria gonorrhoea, syphilis, and/or HIV infections **may be reimbursable** for pregnant women who meet ANY one of the following high-risk criteria:
    - a. Sexually active young individuals under 25 years
    - b. New or multiple sexual partners
    - c. Past history of sexually transmitted diseases (Bacterial Vaginosis, Chancroid, Chlamydia, Gonorrhoea, Genital Herpes, Hepatitis B, Hepatitis C, HIV/AIDS, Human Papillomavirus, Lymphogranuloma Venereum, Syphilis, Trichomoniasis)
    - d. Current sex workers
    - e. Past or current injection drug use
  3. Fetal Fibronectin (FFN) assays **may be reimbursable** for pregnant women who meet ALL of the following criteria:
    - a. Singleton or twin gestations,
    - b. Intact membranes,
    - c. Cervical dilation <3 cm, and
    - d. Patient experiencing symptoms suggestive of preterm labor between 24 and less than 35 weeks' gestation.
  4. Testing pregnant women for thyroid dysfunction **may be reimbursable** if they have any of the following:
    - a. Symptoms of thyroid disease
    - b. Personal history of thyroid disease
    - c. Personal history of other medical conditions associated with thyroid disease (e.g. diabetes mellitus, goiter, iodine deficiency)
  5. Screening for Zika virus testing is covered in accordance with CPCPLAB042 Zika Virus Testing.
  6. Fetal RHD genotyping using maternal plasma **may be reimbursable** in RHD negative pregnant women.

7. All other applications of the FFN assay **is not reimbursable**, including, but not limited to the following:
  - a. As part of routine pregnancy monitoring in asymptomatic women with singleton gestation and no risk factors for preterm birth.
  - b. As part of clinical monitoring of asymptomatic women at high risk for preterm birth, including but not limited to those with multiple gestations, history of preterm birth, uterine malformation, cervical incompetence, or history of two or more spontaneous second trimester abortions.
  - c. As part of clinical monitoring in women with triplet or higher-order gestations, intact membranes, cervical dilation <3 cm, and who are experiencing symptoms suggestive of preterm labor.
  - d. As a test to identify women at term being considered for induction who are likely to deliver within 24–48 hours and therefore, do not require induction.
  
8. Serial monitoring of salivary estriol levels as a technique of risk assessment for preterm labor or delivery **is not reimbursable**.

## Procedure Codes

Codes
80081, 80055, 81001, 81002, 81003, 81007, 81015, 82677, 82731, 82947, 82950, 82951, 82962, 83020, 83021, 83036, 84443, 84999, 85004, 85007, 85009, 85014, 85018, 85025, 85027, 85032, 85041, 85048, 86480, 86580, 86592, 86593, 86631, 86632, 86701, 86702, 86703, 86762, 86787, 86780, 86803, 86804, 86850, 86900, 86901, 87077, 87081, 87086, 87088, 87110, 87270, 87320, 87340, 87341, 87490, 87491, 87590, 87591, 87592, 87653, 87800, 87802, 87810, 87850, G0306, G0307, G0432, G0433, G0435, G0472, S3652

## References:

- ACOG. (2011). ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. *Obstet Gynecol*, 118(1), 197-198. doi:10.1097/AOG.0b013e318227f06b
- ACOG. (2012). Committee opinion No. 533: lead screening during pregnancy and lactation. *Obstet Gynecol*, 120(2 Pt 1), 416-420. doi:10.1097/AOG.0b013e31826804e8
- ACOG. (2014). Committee Opinion No. 614: Management of pregnant women with presumptive exposure to *Listeria monocytogenes*. *Obstet Gynecol*, 124(6), 1241-1244. doi:10.1097/01.AOG.0000457501.73326.6c
- ACOG. (2015a). ACOG Practice Bulletin Number 148: Thyroid disease in pregnancy. *Obstet Gynecol*, 125, 996-1005.
- ACOG. (2015b). Committee opinion no. 634: Hereditary cancer syndromes and risk assessment. *Obstet Gynecol*, 125(6), 1538-1543. doi:10.1097/01.Aog.0000466373.71146.51
- ACOG. (2017b). Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Retrieved from [https://journals.lww.com/greenjournal/fulltext/2017/08000/Practice\\_Bulletin\\_No\\_\\_181\\_\\_Prevention\\_of\\_Rh\\_D.54.aspx](https://journals.lww.com/greenjournal/fulltext/2017/08000/Practice_Bulletin_No__181__Prevention_of_Rh_D.54.aspx)

ACOG. (2017c, 09/2017). Routine Tests During Pregnancy. Retrieved from <https://www.acog.org/Patients/FAQs/Routine-Tests-During-Pregnancy?>

ACOG. (2018a). Committee Opinion No. 757: Screening for Perinatal Depression. *Obstet Gynecol*, 132(5), e208-e212. Retrieved from <https://www.acog.org/-/media/Committee-Opinions/Committee-on-Obstetric-Practice/co757.pdf?dmc=1&ts=20190107T1732311925>

ACOG. (2018b, 08/31/2018). Practice Advisory Interim Guidance for Care of Obstetric Patients During a Zika Virus Outbreak. Practice Advisories. Retrieved from <https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Interim-Guidance-for-Care-of-Obstetric-Patients-During-a-Zika-Virus-Outbreak>

ACOG. (2019a). ACOG Committee Opinion No. 778: Newborn Screening and the Role of the Obstetrician-Gynecologist. *Obstet Gynecol*, 133(5), e357-e361. doi:10.1097/aog.0000000000003245

ACOG. (2019b). Management of Patients in the Context of Zika Virus. Retrieved from <https://www.acog.org/-/media/Committee-Opinions/Immunization-Infectious-Disease-and-Public-Health-Preparedness-Expert-Work-Group/co784.pdf?dmc=1&ts=20200204T1904597658>

ACOG. (2020c). Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797. *Obstet Gynecol*, 135(2), e51-e72. doi:10.1097/aog.0000000000003668

ACOG. (2021a). ACOG Publications: January 2021. *Obstetrics & Gynecology*, 137(1). Retrieved from [https://journals.lww.com/greenjournal/Fulltext/2021/01000/ACOG\\_Publications\\_\\_January\\_2021.31.aspx](https://journals.lww.com/greenjournal/Fulltext/2021/01000/ACOG_Publications__January_2021.31.aspx)

ACOG. (2021b). Consumer Testing for Disease Risk: ACOG Committee Opinion Summary, Number 816. *Obstet Gynecol*, 137(1), 203-204. doi:10.1097/aog.0000000000004201

ADA. (2018). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. *Diabetes Care*, 41(Suppl 1), S13-s27. doi:10.2337/dc18-S002

ADA. (2020). Standards of Medical Care in Diabetes - 2020. Retrieved from [https://care.diabetesjournals.org/content/diacare/suppl/2019/12/20/43.Supplement\\_1.DC1/DC\\_43\\_S1\\_2020.pdf](https://care.diabetesjournals.org/content/diacare/suppl/2019/12/20/43.Supplement_1.DC1/DC_43_S1_2020.pdf)

Calhoun, D. (2020, 3/23/2020). Postnatal diagnosis and management of hemolytic disease of the fetus and newborn. Retrieved from [https://www.uptodate.com/contents/postnatal-diagnosis-and-management-of-hemolytic-disease-of-the-fetus-and-newborn?topicRef=6773&source=see\\_link](https://www.uptodate.com/contents/postnatal-diagnosis-and-management-of-hemolytic-disease-of-the-fetus-and-newborn?topicRef=6773&source=see_link)

CDC. (2015a, 06/04/2015). Bacterial Vaginosis. Retrieved from <https://www.cdc.gov/std/tg2015/bv.htm>

CDC. (2015b, 08/22/2016). Screening Recommendations and Considerations Referenced in Treatment Guidelines and Original Sources. Retrieved from <https://www.cdc.gov/std/tg2015/screening-recommendations.htm>

CDC. (2015c, 10/15/2015). Testing Recommendations for Hepatitis C Virus Infection. Retrieved from <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm>

- CDC. (2019a). NEW Zika and Dengue Testing Guidance (Updated November 2019). Retrieved from <https://www.cdc.gov/zika/hc-providers/testing-guidance.html>
- CDC. (2019b). Pregnancy and HIV, Viral Hepatitis, STD, & TB Prevention Screening Recommendations. Retrieved from <https://www.cdc.gov/nchhstp/pregnancy/screening/index.html>
- CDC. (2020a). CDC Recommendations for Hepatitis C Screening Among Adults in the United States. Retrieved from <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm>
- CDC. (2020b, 6/12/2020). Screening Recommendations. NCHHSTP. Retrieved from <https://www.cdc.gov/nchhstp/pregnancy/screening/index.html>
- Chou, R., Dana, T., Fu, R., Zakher, B., Wagner, J., Ramirez, S., . . . Jou, J. H. (2020). Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *Jama*. doi:10.1001/jama.2019.20788
- Clausen, F. B., Steffensen, R., Christiansen, M., Rudby, M., Jakobsen, M. A., Jakobsen, T. R., . . . Grunnet, N. (2014). Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark. *Prenat Diagn*, 34(10), 1000-1005. doi:10.1002/pd.4419
- Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Cabana, M., Caughey, A. B., . . . Wong, J. B. (2019). Screening for Elevated Blood Lead Levels in Children and Pregnant Women: US Preventive Services Task Force Recommendation Statement. *Jama*, 321(15), 1502-1509. doi:10.1001/jama.2019.3326
- Daniels, G., Finning, K., Martin, P., & Summers, J. (2007). Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin. *Transfus Clin Biol*, 14(6), 568-571. doi:10.1016/j.tracli.2008.03.007
- Darlington, M., Carbone, B., Mailloux, A., Brossard, Y., Levy-Mozziconacci, A., Cortey, A., . . . Durand-Zaleski, I. (2018). Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women. *BMC Pregnancy Childbirth*, 18(1), 496. doi:10.1186/s12884-018-2114-5
- de Haas, M., Thurik, F. F., van der Ploeg, C. P., Veldhuisen, B., Hirschberg, H., Soussan, A. A., . . . Ellen van der Schoot, C. (2016). Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. *Bmj*, 355, i5789. doi:10.1136/bmj.i5789
- de Jong, A., Maya, I., & van Lith, J. M. (2015). Prenatal screening: current practice, new developments, ethical challenges. *Bioethics*, 29(1), 1-8. doi:10.1111/bioe.12123
- Dondorp, W., de Wert, G., Bombard, Y., Bianchi, D. W., Bergmann, C., Borry, P., . . . American Society of Human, G. (2015). Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. *European journal of human genetics : EJHG*, 23(11), 1438-1450. doi:10.1038/ejhg.2015.57
- Finning, K., Martin, P., Summers, J., Massey, E., Poole, G., & Daniels, G. (2008). Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. *Bmj*, 336(7648), 816-818. doi:10.1136/bmj.39518.463206.25

Fung, K. F. K., & Eason, E. (2018). No. 133-Prevention of Rh Alloimmunization. *J Obstet Gynaecol Can*, 40(1), e1-e10. doi:10.1016/j.jogc.2017.11.007

Grant, A., & Mohide, P. (1982). Screening and diagnostic tests in antenatal care. Effectiveness and satisfaction in antenatal care, 22-59. Retrieved from <https://books.google.com/books?hl=en&lr=&id=fVH-JYbe2isC&oi=fnd&pg=PA22&dq=screening+versus+diagnostic+tests&ots=WXVxt6ALwT&sig=DUy8K33sGYU72yPEjPHlyTT3ppA#v=onepage&q=screening%20versus%20diagnostic%20tests&f=false>

Gregg, A. R., Skotko, B. G., Benkendorf, J. L., Monaghan, K. G., Bajaj, K., Best, R. G., . . . Watson, M. S. (2016). Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. *Genet Med*, 18(10), 1056-1065. doi:10.1038/gim.2016.97

HRSA. (2017, October 2017). Women's Preventive Services Guidelines. Retrieved from <https://www.hrsa.gov/womens-guidelines-2016/index.html>

HRSA. (2019). Women's Preventive Services Guidelines. Retrieved from <https://www.hrsa.gov/womens-guidelines-2019>

Johnson, J. A., MacDonald, K., Clarke, G., & Skoll, A. (2017). No. 343-Routine Non-invasive Prenatal Prediction of Fetal RHD Genotype in Canada: The Time is Here. *J Obstet Gynaecol Can*, 39(5), 366-373. doi:10.1016/j.jogc.2016.12.006

Kent, J., Farrell, A. M., & Soothill, P. (2014). Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. *BMC Pregnancy Childbirth*, 14, 87. doi:10.1186/1471-2393-14-87

Krist, A. H., Davidson, K. W., Mangione, C. M., Barry, M. J., Cabana, M., Caughey, A. B., . . . Wong, J. B. (2020). Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement. *Jama*, 323(22), 2301-2309. doi:10.1001/jama.2020.8020

LabCorp. (2020). Inheritest. Retrieved from <https://www.integratedgenetics.com/patients/pre-pregnancy/inheritest>

LeFevre, M. L., & USPSTF. (2014). Screening for Chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*, 161(12), 902-910. doi:10.7326/m14-1981

Lockwood, C. J., & Magriples, U. (2020, 12/9/2020). Prenatal care: Initial assessment. UpToDate. Retrieved from <https://www.uptodate.com/contents/prenatal-care-initial-assessment>

Moise, K. (2020, 12/16/2020). Prevention of RhD alloimmunization in pregnancy. Retrieved from <https://www.uptodate.com/contents/prevention-of-rhd-alloimmunization-in-pregnancy>

Moyer, V. A. (2014). Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*, 160(6), 414-420. doi:10.7326/m13-2905

Moyer, V. A., & USPSTF. (2013a). Screening for hepatitis c virus infection in adults: U.S. preventive services task force recommendation statement. *Ann Intern Med*, 159(5), 349-357. doi:10.7326/0003-4819-159-5-201309030-00672

Moyer, V. A., & USPSTF. (2013b). Screening for hiv: U.S. preventive services task force recommendation statement. *Ann Intern Med*, 159(1), 51-60. doi:10.7326/0003-4819-159-1-201307020-00645

NICE. (2016). High-throughput non-invasive prenatal testing for fetal RHD genotype. Retrieved from <https://www.nice.org.uk/guidance/dg25/chapter/1-Recommendations>

NICE. (2020). Antenatal care for uncomplicated pregnancies: screening. In: NICE.

Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., . . . Wong, J. B. (2019). Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement. *Jama*, 321(23), 2326-2336. doi:10.1001/jama.2019.6587

Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., . . . Wong, J. B. (2020). Screening for Bacterial Vaginosis in Pregnant Persons to Prevent Preterm Delivery: U.S. Preventive Services Task Force Recommendation Statement. *Jama*, 323(13), 1286-1292. doi:10.1001/jama.2020.2684

Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., . . . Wong, J. B. (2019). Screening for Hepatitis B Virus Infection in Pregnant Women: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. *Jama*, 322(4), 349-354. doi:10.1001/jama.2019.9365

Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., . . . Wong, J. B. (2019). Screening for Asymptomatic Bacteriuria in Adults: U.S. Preventive Services Task Force Recommendation Statement. *Jama*, 322(12), 1188-1194. doi:10.1001/jama.2019.13069

Pollock, L., Cohan, D., Pecci, C. C., & Mittal, P. (2019). ACOG Committee Opinion No. 752: Prenatal and Perinatal Human Immunodeficiency Virus Testing. *Obstet Gynecol*, 133(1), 187. doi:10.1097/aog.0000000000003048

RCOG. (2014). The Management of Women with Red Cell Antibodies during Pregnancy. Retrieved from [https://www.rcog.org.uk/globalassets/documents/guidelines/rbc\\_gtg65.pdf](https://www.rcog.org.uk/globalassets/documents/guidelines/rbc_gtg65.pdf)

Rink, B., Biggio, J., Kamyar, M., & ACOG. (2017). Committee Opinion No. 724: Consumer Testing for Disease Risk. *Obstet Gynecol*, 130(5), e270-e273. doi:10.1097/aog.0000000000002401

Runkel, B., Bein, G., Sieben, W., Sow, D., Polus, S., & Fler, D. (2020). Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review. *BMC Pregnancy Childbirth*, 20(1), 83. doi:10.1186/s12884-020-2742-4

Sandler, S. G., Flegel, W. A., Westhoff, C. M., Denomme, G. A., Delaney, M., Keller, M. A., . . . Simon, C. D. (2015). It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group. *Transfusion*, 55(3), 680-689. doi:10.1111/trf.12941

Schrag, S., Gorwitz, R., Fultz-Butts, K., & Schuchat, A. (2002). Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. *MMWR Recomm Rep*, 51(Rr-11), 1-22. Retrieved from <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5111a1.htm>



- Siu, A. L. (2015). Screening for Iron Deficiency Anemia and Iron Supplementation in Pregnant Women to Improve Maternal Health and Birth Outcomes: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med*, 163(7), 529-536. doi:10.7326/m15-1707
- Siu, A. L., & USPSTF. (2016). Screening for depression in adults: U.S. preventive services task force recommendation statement. *Jama*, 315(4), 380-387. doi:10.1001/jama.2015.18392
- Slutsker, J. S., Hennessy, R. R., & Schillinger, J. A. (2018). Factors Contributing to Congenital Syphilis Cases - New York City, 2010-2016. *MMWR Morb Mortal Wkly Rep*, 67(39), 1088-1093. doi:10.15585/mmwr.mm6739a3
- USPSTF. (2005). Screening for Rh(D) Incompatibility: Recommendation Statement. *Am Fam Physician*. Retrieved from <https://www.aafp.org/afp/2005/0915/p1087.html>
- USPSTF. (2006). Screening for elevated blood lead levels in children and pregnant women. *Pediatrics*, 118(6), 2514-2518. doi:10.1542/peds.2006-2352
- USPSTF. (2008a). Screening for asymptomatic bacteriuria in adults: U.S. preventive services task force reaffirmation recommendation statement. *Ann Intern Med*, 149(1), 43-47. doi:10.7326/0003-4819-149-1-200807010-00009
- USPSTF. (2008b). Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*, 148(3), 214-219.
- USPSTF. (2009). Screening for hepatitis B virus infection in pregnancy: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med*, 150(12), 869-873, w154.
- USPSTF. (2016). Serologic screening for genital herpes infection: U.S. preventive services task force recommendation statement. *Jama*, 316(23), 2525-2530. doi:10.1001/jama.2016.16776
- USPSTF. (2018). Screening for syphilis infection in pregnant women: U.S. preventive services task force reaffirmation recommendation statement. *Jama*, 320(9), 911-917. doi:10.1001/jama.2018.11785
- USPSTF. (2019). Hepatitis B Virus Infection in Pregnant Women: Screening. Retrieved from <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-b-virus-infection-in-pregnant-women-screening?ds=1&s=hepatitis%20B>
- VA, & DOD. (2018). VA/DOD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF PREGNANCY. Washington, D.C.: Department of Veterans Affairs Retrieved from <https://www.healthquality.va.gov/guidelines/WH/up/VADoDPregnancyCPG4102018.pdf>
- Vockley, J., Andersson, H. C., Antshel, K. M., Braverman, N. E., Burton, B. K., Frazier, D. M., . . . Berry, S. A. (2014). Phenylalanine hydroxylase deficiency: diagnosis and management guideline. *Genet Med*, 16(2), 188-200. doi:10.1038/gim.2013.157
- WHO. (2016). WHO recommendations on antenatal care for a positive pregnancy experience: World Health Organization.



Yang, H., Llewellyn, A., Walker, R., Harden, M., Saramago, P., Griffin, S., & Simmonds, M. (2019). High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis. *BMC Med*, 17(1), 37. doi:10.1186/s12916-019-1254-4

**Policy Update History:**

5/1/2022	New policy
----------	------------